The blue coloration of magic mushrooms is a chemical reaction triggered by damage or stress. This process, similar to how an apple turns brown when cut, is due to the oxidation of psilocybin, the psychoactive compound in these mushrooms.
One possible reason for this phenomenon is psilocybin’s interaction with the thalamus, the section of our brain that receives sensory information and relays it to different brain areas for processing.
This year’s holiday gift guide celebrates psychedelics and nods to those who appreciate the profound and the extraordinary.
Delving into 5 legal ways to explore psychedelic experiences, and the potential risks of using these hallucinogenic substances.
The evidence pile for psilocybin’s efficacy in treating depression is growing with new data demonstrating 79% remission rates after two doses. Meanwhile, early trials hint at MEAI’s efficacy in treating obesity, ketamine studies suggest a single dose is effective in treating anxiety and discussions arise about psychedelic use and its capacity to birth new environmentalists.
Classic psychedelics might effectively kill pain with even greater vigor over time, sharply contrasting with opioids.
Tidal Wave mushrooms have made a splash in the psychedelic community since their creation, and for good reason. This hybrid strain, created by Magic Myco and winner of the inaugural Psilocybin Cup, wowed users due to its unprecedented potency.
Psilocybin use shows reduced psychological distress in individuals with adverse childhood experiences, while microdosing shows a “both and” approach to treating ADHD.
A new study exploring real-world psychedelic microdosing for ADHD could help reimagine the way we perceive and treat the condition.
“The PAC behind this ballot question rigged the rules for psychedelic services in Oregon, where people are now charged around $3,500 for a gram of psilocybin mushrooms that normally costs $10. We will not let this entity corner life-saving treatments in our Commonwealth,” remarked James Davis, Bay Staters for Natural Medicine Cofounder and a former staffer for the Massachusetts legislature’s Joint Committee on Cannabis Policy.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.